Cladribine

This classification denotes a radiosensitizing agent and purine antagonist with the molecular formula C10H12ClN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 47M74X9YT5, chemically known as adenosine, 2-chloro-2-deoxy- but more generally known as cladribine, which bears US NIH Compound Identifier 1546. European Medicines Agency schedules Cladribine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06635MIG. The term CLADRIBINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). World Health Organization schedules cladribine in its Anatomical Therapeutic Chemical (ATC) Classification. CLADRIBINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cladribine under HS 29349990 and SITC 51579. As of Q4 2014, CLADRIBINE remains US FDA's Preferred Term for this commodity. Cladribine bears US NLM identifiers UMLS ID C0092801 and NCI Concept Code C1336. SMILES: C1C(C(OC1N2C=NC3=C2N=C(N=C3N)CL)CO)O.